Clinical trial · Observational
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies. RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia. Mathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.
Conditions
Conditions (58)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenovirus | — | UNRESOLVED | — |
| Arenavirus Infections | — | UNRESOLVED | — |
| Ascaris Lumbricoides | — | UNRESOLVED | — |
| Brucellosis | — | UNRESOLVED | — |
| Chikungunya | — | UNRESOLVED | — |
| Chlamydia | — | UNRESOLVED | — |
| Clonorchis Sinensis | — | UNRESOLVED | — |
| Cytomegalovirus | — | UNRESOLVED | — |
| Dengue | — | UNRESOLVED | — |
| Diphteria | — | UNRESOLVED |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Human Community Cohort (National Population Sample)
- description
- Probability-based, multi-stage population sample of \~10,000 participants (2-75 years old) recruited across urban and rural communities nationwide. Data include standardized questionnaires (demography, health conditions, mobility, animal contact, healthcare access) and serum biospecimens for multiplex serology;
Primary outcomes (1)
- measure
- Seroprevalence of antibodies against an established panel of priority pathogens in the surveyed human populations:
- timeFrame
- At the time of blood sampling during household visits, over the inclusion period from December 2025 to April 2026.
- description
- The proportion of sampled individuals with detectable antibodies against this priority panel of pathogens, measured using multiplex serological assays.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Residency in the village for more than 6 months; * Age between 2 and 75 years old at the time of inclusion; * For adults: provision of written consent; * For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years; Exclusion Criteria: * Unable to understand or consent; * Under guardianship or deprived of liberty; * Medical conditions that impede survey participation; * Refusal to participate in the study.
References
Publications (0)
Data not yet available